Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has reported Operating Leases for 7 consecutive years, with $12.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases fell 40.77% year-over-year to $12.1 million; the TTM figure through Dec 2025 stood at $12.1 million (down 40.77% YoY), while the FY2025 annual figure was $12.1 million, down 40.77% from the prior year.
• Operating Leases fell to $12.1 million in Q4 2025 per EDIT's latest filing, from $13.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $32.9 million in Q4 2022 and bottomed at $9.3 million in Q3 2022.
• Historically, Operating Leases has averaged $19.5 million across 5 years, with a median of $20.4 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases tumbled 52.5% — and 2023, when it surged 167.13%.
• Editas Medicine's Operating Leases stood at $16.1 million in 2021, then jumped by 104.52% to $32.9 million in 2022, then fell by 25.84% to $24.4 million in 2023, then dropped by 16.38% to $20.4 million in 2024, then tumbled by 40.77% to $12.1 million in 2025.
• Business Quant data shows EDIT's Operating Leases at $12.1 million in Q4 2025, $13.6 million in Q3 2025, and $15.0 million in Q2 2025.